These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 25761545

  • 1. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
    Grau S, Lozano V, Valladares A, Cavanillas R, Xie Y, Nocea G.
    Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
    Jansen JP, Kumar R, Carmeli Y.
    Value Health; 2009 Aug; 12(2):234-44. PubMed ID: 20667059
    [Abstract] [Full Text] [Related]

  • 3. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
    Jansen JP, Kumar R, Carmeli Y.
    Pharmacoeconomics; 2009 Aug; 27(12):1045-56. PubMed ID: 19908928
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK.
    Prabhu V, Foo J, Ahir H, Sarpong E, Merchant S.
    J Med Econ; 2017 Aug; 20(8):840-849. PubMed ID: 28532194
    [Abstract] [Full Text] [Related]

  • 5. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
    Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA.
    Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
    [Abstract] [Full Text] [Related]

  • 6. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
    Tellado J, Woods GL, Gesser R, McCarroll K, Teppler H.
    Surg Infect (Larchmt); 2002 Feb; 3(4):303-14. PubMed ID: 12697078
    [Abstract] [Full Text] [Related]

  • 7. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V, Teppler H, Protocol 017 Study Group.
    Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
    [Abstract] [Full Text] [Related]

  • 8. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
    Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA.
    Am J Health Syst Pharm; 2007 May 15; 64(10):1080-6. PubMed ID: 17494908
    [Abstract] [Full Text] [Related]

  • 9. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
    Zakrison TL, Hille DA, Namias N.
    Surg Infect (Larchmt); 2012 Feb 15; 13(1):38-42. PubMed ID: 22217196
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
    Gesser RM, McCarroll K, Teppler H, Woods GL.
    J Antimicrob Chemother; 2003 May 15; 51(5):1253-60. PubMed ID: 12697633
    [Abstract] [Full Text] [Related]

  • 11. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H.
    Antimicrob Agents Chemother; 2005 Aug 15; 49(8):3217-21. PubMed ID: 16048928
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
    Teppler H, McCarroll K, Gesser RM, Woods GL.
    Surg Infect (Larchmt); 2002 Aug 15; 3(4):337-49. PubMed ID: 12697080
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
    Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, Sen SS, Basu A.
    BMC Infect Dis; 2017 Apr 28; 17(1):314. PubMed ID: 28454524
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of ertapenem.
    Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, Mistry G, Isaacs R.
    J Antimicrob Chemother; 2004 Jun 28; 53 Suppl 2():ii75-81. PubMed ID: 15150186
    [Abstract] [Full Text] [Related]

  • 17. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S, Higareda I, Angel-Muller E, Ismail M, Hague C, Adeyi B, Woods GL, Teppler H, Protocol 023 Study Group.
    Infect Dis Obstet Gynecol; 2003 Jun 28; 11(1):27-37. PubMed ID: 12839630
    [Abstract] [Full Text] [Related]

  • 18. [New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
    Barboza E, Solomkin J, Goldstein EJ, del Castillo M, Alvarado R, Barboza A, Teppler H.
    Rev Gastroenterol Peru; 2003 Jun 28; 23(3):192-8. PubMed ID: 14532920
    [Abstract] [Full Text] [Related]

  • 19. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M, Plosker GL.
    Pharmacoeconomics; 2001 Jun 28; 19(11):1135-75. PubMed ID: 11735679
    [Abstract] [Full Text] [Related]

  • 20. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
    Xu ZR, Ran XW, Xian Y, Yan XD, Yuan GY, Mu SM, Shen JF, Zhang BS, Gan WJ, Wang J.
    J Antimicrob Chemother; 2016 Jun 28; 71(6):1688-96. PubMed ID: 26888908
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.